Literature DB >> 22441321

T-cell-based immunosuppressive therapy inhibits the development of natural antibodies in infant baboons.

Eefje M Dons1, Claudia Montoya, Cassandra E Long, Hidetaka Hara, Gabriel J Echeverri, Burcin Ekser, Corin Ezzelarab, Dasha Roa Medellin, Dirk J van der Windt, Noriko Murase, Lora H Rigatti, Robert Wagner, Roman F Wolf, Mohamed Ezzelarab, Lori J West, Jan N M Ijzermans, David K C Cooper.   

Abstract

BACKGROUND: We set out to determine whether B-cell tolerance to A/B-incompatible alloantigens and pig xenoantigens could be achieved in infant baboons.
METHODS: Artery patch grafts were implanted in the abdominal aorta in 3-month-old baboons using A/B-incompatible (AB-I) allografts or wild-type pig xenografts (pig). Group 1 (Gp1) (controls, n=6) received no immunosuppressive therapy (IS) and no graft. Gp2 (n=2) received an AB-I or pig graft but no IS. Gp3 received AB-I grafts+IS (Gp3A: n=2) or pig grafts+IS (Gp3B: n=2). IS consisted of ATG, anti-CD154mAb, and mycophenolate mofetil until age 8 to 12 months. Gp4 (n=2) received IS only but no graft.
RESULTS: In Gp1, anti-A/B and cytotoxic anti-pig immunoglobulin-M increased steadily during the first year. Gp2 became sensitized to donor-specific AB-I or pig antigens within 2 weeks. Gp3 and Gp4 infants that received anti-CD154mAb made no or minimal anti-A/B and anti-pig antibodies while receiving IS. DISCUSSION: The production of natural anti-A/B and anti-pig antibodies was inhibited by IS with anti-CD154mAb, even in the absence of an allograft or xenograft, suggesting that natural antibodies may not be entirely T-cell independent. These data are in contrast to clinical experience with AB-I allotransplantation in infants, who cease producing only donor-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441321      PMCID: PMC3776575          DOI: 10.1097/TP.0b013e3182481168

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  42 in total

1.  Antibody responses in early graft rejection in pig-to-primate renal xenotransplantation.

Authors:  B J Holmes; A Richards; M McLaughlin; G Cruz; L Copeman; S Bycroft; H Schuurman; D J White; H Davies; E Cozzi
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

2.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.

Authors:  T Kawai; D Andrews; R B Colvin; D H Sachs; A B Cosimi
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  The role of T cell help in the production of antibodies specific for Gal alpha 1-3Gal.

Authors:  Nathalie Cretin; Jennifer Bracy; Krista Hanson; John Iacomini
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

4.  Anti-CD154 monoclonal antibody and thromboembolism revisted.

Authors:  Christoph Knosalla; Bernd Gollackner; David K Cooper
Journal:  Transplantation       Date:  2002-08-15       Impact factor: 4.939

5.  ABO-incompatible heart transplantation in infants.

Authors:  L J West; S M Pollock-Barziv; A I Dipchand; K J Lee; C J Cardella; L N Benson; I M Rebeyka; J G Coles
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

6.  Generation of a specific-pathogen-free baboon colony.

Authors:  Roman F Wolf; Richard Eberle; Gary L White
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-11       Impact factor: 1.232

7.  CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.

Authors:  M Mihara; I Tan; Y Chuzhin; B Reddy; L Budhai; A Holzer; Y Gu; A Davidson
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

8.  Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DR-BB rat.

Authors:  K L Kover; Z Geng; D M Hess; C D Benjamin; W V Moore
Journal:  Diabetes       Date:  2000-10       Impact factor: 9.461

9.  Production of alpha 1,3-galactosyltransferase-deficient pigs.

Authors:  Carol J Phelps; Chihiro Koike; Todd D Vaught; Jeremy Boone; Kevin D Wells; Shu-Hung Chen; Suyapa Ball; Susan M Specht; Irina A Polejaeva; Jeff A Monahan; Pete M Jobst; Sugandha B Sharma; Ashley E Lamborn; Amy S Garst; Marilyn Moore; Anthony J Demetris; William A Rudert; Rita Bottino; Suzanne Bertera; Massimo Trucco; Thomas E Starzl; Yifan Dai; David L Ayares
Journal:  Science       Date:  2002-12-19       Impact factor: 47.728

10.  Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.

Authors:  Bruce E Loveland; Julie Milland; Peter Kyriakou; Bruce R Thorley; Dale Christiansen; Marc B Lanteri; Mark Regensburg; Maureen Duffield; Andrew J French; Lindsay Williams; Louise Baker; Malcolm R Brandon; Pei-Xiang Xing; Del Kahn; Ian F C McKenzie
Journal:  Xenotransplantation       Date:  2004-03       Impact factor: 3.907

View more
  9 in total

1.  Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.

Authors:  Hidetaka Hara; Andrew Bentall; Cassandra Long; Jason Fang; Oleg Andreyev; John Lunz; Mohamed Ezzelarab; Kareem M Abu-Elmagd; Ron Shapiro; David Ayares; Mark Stegall; David K C Cooper
Journal:  Xenotransplantation       Date:  2013-09-03       Impact factor: 3.907

2.  Is there a correlation between anti-pig antibody levels in humans and geographic location during childhood?

Authors:  Goutham Kumar; Vikas Satyananda; Jason Fang; Hao Zhou; Minoru Fujita; Burcin Ekser; Cassandra Long; Eefje Dons; Qing Sun; David Ayares; Hidetaka Hara; David K C Cooper
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

Review 3.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

4.  Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs.

Authors:  Whayoung Lee; Hidetaka Hara; Mohamed B Ezzelarab; Hayato Iwase; Rita Bottino; Cassandra Long; Jagdeece Ramsoondar; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2016-03-14       Impact factor: 3.907

5.  A desirable transgenic strategy using GGTA1 endogenous promoter-mediated knock-in for xenotransplantation model.

Authors:  Nayoung Ko; Joohyun Shim; Hyoung-Joo Kim; Yongjin Lee; Jae-Kyung Park; Kyungmin Kwak; Jeong-Woong Lee; Dong-Il Jin; Hyunil Kim; Kimyung Choi
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

Review 6.  Immunobiological barriers to xenotransplantation.

Authors:  David K C Cooper; Burcin Ekser; A Joseph Tector
Journal:  Int J Surg       Date:  2015-07-06       Impact factor: 6.071

7.  Are there advantages in the use of specific pathogen-free baboons in pig organ xenotransplantation models?

Authors:  Huidong Zhou; Hayato Iwase; Roman F Wolf; Burcin Ekser; Mohamed Ezzelarab; Hidetaka Hara; Gary White; David K C Cooper
Journal:  Xenotransplantation       Date:  2014-02-18       Impact factor: 3.907

Review 8.  Modifying the sugar icing on the transplantation cake.

Authors:  David K C Cooper
Journal:  Glycobiology       Date:  2016-03-01       Impact factor: 4.313

Review 9.  The immune system in infants: Relevance to xenotransplantation.

Authors:  Mohamed Bikhet; Mahmoud Morsi; Hidetaka Hara; Leslie A Rhodes; Waldemar F Carlo; David Cleveland; David K C Cooper; Hayato Iwase
Journal:  Pediatr Transplant       Date:  2020-08-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.